Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC boosted its position in Cardiff Oncology, Inc. (NASDAQ:CRDF) by 1.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 928,232 shares of the company’s stock after acquiring an additional 17,557 shares during the quarter. Geode Capital Management LLC owned 1.82% of Cardiff Oncology worth $2,479,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Charles Schwab Investment Management Inc. grew its stake in shares of Cardiff Oncology by 11.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 121,293 shares of the company’s stock worth $324,000 after purchasing an additional 12,503 shares in the last quarter. State Street Corp boosted its position in shares of Cardiff Oncology by 3.4% during the 3rd quarter. State Street Corp now owns 832,652 shares of the company’s stock worth $2,223,000 after acquiring an additional 27,628 shares in the last quarter. Blair William & Co. IL boosted its position in shares of Cardiff Oncology by 32.2% during the 2nd quarter. Blair William & Co. IL now owns 227,630 shares of the company’s stock worth $505,000 after acquiring an additional 55,450 shares in the last quarter. Point72 DIFC Ltd acquired a new position in Cardiff Oncology in the second quarter valued at approximately $27,000. Finally, GSA Capital Partners LLP increased its stake in Cardiff Oncology by 432.7% in the third quarter. GSA Capital Partners LLP now owns 186,650 shares of the company’s stock valued at $498,000 after purchasing an additional 151,613 shares during the last quarter. 16.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. HC Wainwright cut their price target on shares of Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Piper Sandler lifted their price target on Cardiff Oncology from $7.00 to $10.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th.

Cardiff Oncology Stock Performance

Shares of Cardiff Oncology stock opened at $4.11 on Wednesday. The company has a market capitalization of $210.16 million, a P/E ratio of -4.37 and a beta of 1.76. Cardiff Oncology, Inc. has a 1 year low of $1.44 and a 1 year high of $6.42. The company’s fifty day moving average is $3.43 and its two-hundred day moving average is $2.79.

Insider Buying and Selling

In related news, Director Gary W. Pace purchased 350,115 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The stock was purchased at an average cost of $2.60 per share, with a total value of $910,299.00. Following the completion of the acquisition, the director now directly owns 1,047,876 shares in the company, valued at $2,724,477.60. This trade represents a 50.18 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 7.80% of the company’s stock.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.